Need for a larger cohort to study these mutations in ESCC

Further investigations in a larger cohort of patient samples are needed to confirm this link and to better understand the role of EGFR mutations in ESCC tumorigenesis in AA patients. This research could lead to the development of targeted therapies that are specifically tailored to AA patients with ESCC.
Here are some specific areas of research that could be explored:
Investigating these aspects could lead to improved outcomes for AA patients with ESCC. Targeted therapies that are specifically tailored to AA patients could provide a more effective treatment option and could help to reduce the high mortality rates of this disease in the AA population.